WVE / Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2022 Results - Earnings Call Transcript

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal

Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 tri more_horizontal

Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor R more_horizontal

Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to lo more_horizontal

Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade) more_horizontal

Wave Life Sciences (WVE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.6 more_horizontal

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the num more_horizontal

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy more_horizontal